An ongoing dialogue on HIV/AIDS, infectious diseases,
February 17th, 2013
An Adherence Intervention That Works — But There’s a Catch
In a previous post, we reviewed the various flavors of medication non-adherence, and concluded with this tantalizing line:
Next up: An Adherence Intervention that Actually Works — But There’s a Catch
Well here it is, just published online in JAMA Internal Medicine.
Dr. Robert Gross (a long-time HIV adherence researcher from U Penn) and colleagues enrolled 180 patients with HIV RNA of 1000 or higher who were starting or changing their HIV regimen. They were randomized to usual care versus an adherence intervention called Managed Problem Solving, or “MAPS”. The study took place in three outpatient clinics in Philadelphia; study subjects could be treatment-naive or treatment-experienced. Participants were predominantly black, and 60% were men.
So what constituted MAPS? A trained “interventionist” — someone who went through 15 hours of study-specific education — met with the patient for 4 in-person sessions, some as long as 90 minutes; this was supplemented with 12 subsequent phone calls and then additional monthly calls for a year.
The good news is that the intervention worked: Those in the MAPS group had a 1.78 (95% CI, 1.07-2.96) times greater chance of being in a higher adherence category than those receiving usual care, and there was a strong trend toward a higher likelihood of virologic suppression as well. Of note, 36% of the MAPS group and 26% of those in usual care dropped out of the study, a rate substantially higher than in most clinical trials of antiretroviral therapy, strongly suggesting this was a difficult-to-treat patient population.
So what’s the catch? To say that the MAPS intervention would be difficult to institute in a non-study setting is a colossal understatement, as the vast majority of HIV clinics could never deploy the training, the personnel, or the time for this kind of extra care. While the study authors argue that this intervention would nonetheless meet criteria for cost-effectiveness, such analyses typically take a societal perspective, and would not make MAPS feasible in a clinic with a limited budget.
The solution? Editorialists argue for “real time” adherence monitoring using electronic pill containers connected to a central server through mobile networks. When in place, clinicians could detect individual lapses in pill-taking behavior, and intervene only for people who need it. (Presumably they could also use portable jet-packs to go visit those who need a house call.)
I do think this paper shows some progress in addressing the tricky problem of non-adherent patients (at least those who show up for care). It also demonstrates just how hard it will be to improve adherence, at least until we have some way of identifying ahead of time — or in real-time, as suggested by the editorial — people who are bad at taking their meds.
Until then, enjoy this nifty 2-minute video on the HIV cascade from the CDC — your taxpayer dollars at work!
Categories: Health Care, HIV, Medical Education, Patient Care, Research
Tags: adherence, antiretroviral therapy, HIV
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
One Response to “An Adherence Intervention That Works — But There’s a Catch”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
-
From the Blog — Most Recent Articles
- Florida Moves to Cut AIDS Drug Assistance Program — and Drops the Most Prescribed HIV Regimen in the Country January 27, 2026
- Rabies Is Terrifying — and the Challenge of Managing a Low Risk of a Dreadful Disease January 21, 2026
- Influenza — So Familiar, Still So Mysterious January 14, 2026
- How the Z-Pak Took Over Outpatient Medicine, Part 2: The Reckoning January 6, 2026
- How the Z-Pak Took Over Outpatient Medicine December 29, 2025
FROM NEJM — Recent Infectious Disease Articles- The Essential Role of States in Protecting Immunization Access January 29, 2026In the face of U.S. federal policy shifts that threaten to destabilize vaccine access and weaken clinical guidance, states can step in and protect their residents.
- Case 4-2026: An 80-Year-Old Woman with Cough and Hypoxemia January 29, 2026An 80-year-old woman was admitted to the hospital because of cough and hypoxemia (oxygen saturation, 83%). CT of the chest showed diffuse ground-glass opacities in both lungs. A diagnosis was made.
- A New Therapeutic Broadcast on Hepatitis D, a Satellite Virus January 22, 2026Hepatitis D virus (HDV) is known as a satellite virus because it requires the hepatitis B virus (HBV) surface antigen (HBsAg) to enter the hepatocytes and to complete its life cycle. HDV is the smallest human pathogen, with a single-stranded RNA genome that is approximately 1.7 kb long. Yet, chronic...
- Pneumocystis jirovecii Pneumonia January 22, 2026A 60-year-old man with recently diagnosed HIV infection presented with a 10-day history of fever, dry cough, and shortness of breath. A CT scan of the chest showed diffuse nodules and ground-glass opacities.
- Case 3-2026: A 58-Year-Old Woman with Diplopia and Fever January 22, 2026A 58-year-old woman was admitted to the hospital 3 weeks after lumbar surgery because of diplopia and fever. Left leg pain and a rash had preceded the fever and diplopia. A diagnosis was made.
- The Essential Role of States in Protecting Immunization Access January 29, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

Inerventionist, health coach, case manager, health promotor, DOT specialist, maybe we just haven’t hit on the right title!